Table 6.
ATE analysis of drug class; outcome: depression at all follow-ups
| Estimate | P-value | |
|---|---|---|
| SNRI as reference treatment | ||
| (Intercept) | 0.71 | <2 × 10−16 |
| NDRI | −0.11 | 0.00082 |
| Phenylpiperazine | 0.032 | 0.27 |
| SSRI | −0.031 | 0.013 |
| TCA | 0.058 | 0.16 |
| TeCA | 0.050 | 0.0091 |
| Unique | 0.054 | 0.18 |
| SNRI as reference treatment, doubly robust estimation | ||
| (Intercept) | 0.66 | <2 × 10−16 |
| NDRI | −0.111 | 0.0045 |
| Phenylpiperazine | −0.049 | 0.14 |
| SSRI | −0.045 | 0.00069 |
| TCA | 0.015 | 0.75 |
| TeCA | −0.019 | 0.38 |
| Unique | 0.012 | 0.77 |
| Age | −0.00045 | 0.64 |
| Sex (Male) | 0.00099 | 0.96 |
| Disease progression score | −0.0060 | 0.021 |
| SSRI risk factors | −0.0057 | 0.049 |
| Comorbidities | 0.026 | 0.27 |
| Number of antidepressants | 0.023 | <2 × 10−16 |
| Sedative | 0.095 | 0.0017 |
| Fluoxetine equivalent dose (mg) | 1.28 × 10−5 | 0.029 |
ATE, actual treatment effect, SSRI, selective serotonin reuptake inhibitor, NDRI, norepinephrine–dopamine reuptake inhibitor; SNRI, serotonin–norepinephrine reuptake inhibitor; TCA, tricyclic antidepressant; TARC, tetracyclic and related antidepressants.